Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products
Award Notice Posted
- Solicitation number
- 75N95025R00005
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Sri International
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N95026D00003 Federal IDV award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Place of performance
- Lexington, Kentucky 40509, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases awarded a competitive multiple-award IDIQ to Murty Pharmaceuticals, Inc. for chemistry, manufacturing, and controls and related services for development of drug products, with a contract value of $49,885,703 and award date of July 1, 2026.
The ordering period runs July 1, 2026 through July 31, 2031. Task orders issued under this contract will be cost-reimbursement, term/completion type in most cases; the government determined that fixed-price task orders are not feasible due to the absence of precise specifications and the difficulty of estimating costs with accuracy in this science-responsive, result-driven requirement. Fixed-price task orders may be issued where appropriate and feasible. The contractor is eligible for task orders under Technical Area 1. The award followed unrestricted competition and used no set-aside.
Notice text
A competitive multiple award, Indefinite Delivery/Indefinite Quantity (ID/IQ) type contract was awarded, with a ordering period (July 1, 2026 through July 31, 2031). It is anticipated that Task Orders issued against these contracts will most likely be cost-reimbursement, term/completion type Task Orders. Upon analysis of the type of work and all associated costs involved, fixed-price type task orders are usually not feasible due to the absence of precise specifications and difficulties in estimating costs with accuracy. Based upon the uncertainties involved, the Government would assume undue risk in attempting to fit relatively dynamic (science responsive and result-drive) requirement into a fixed-price environment. In these instances, fixed-price task orders would be disadvantageous to the Government, since they do not provide the Government with the flexibility that is needed to reasonably and responsively shift with the evolving needs of this requirement. However, fixed price Task Order may be issued, where appropriate and feasible.
The Contractor is eligible for Task Orders under Technical Area 1.
The award notice is in relation to Solicitation # 75N95025R00005.
Awarded contract 75N95026D00003 to MURTY PHARMACEUTICALS, INC. for 49885703.00 on 2026-07-01.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products | Award Notice | |
| This notice | Award Notice | |
| Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products | Award Notice | |
| Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products | Award Notice | |
| Chemistry, Manufacturing and Controls and Related Services for Development of Drug Products | Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity